Oct 3, 2022 · NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of …

May 10, 2022 · Pfizer to commercialize NURTEC® ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need. Expands …

Oct 5, 2022 · On Tuesday, Biohaven Ltd. officially launched as a newly independent company, spun out of its former parent as part of Pfizer’s $11.6 billion acquisition, which closed on Oct. 3.

Jan 24, 2025 · Pharmaceutical company Pfizer Inc. (Pfizer), on behalf of its wholly-owned subsidiary Biohaven Pharmaceutical Holding Company Ltd. (Biohaven), has agreed to pay …

May 10, 2022 · Pfizer will pay $11.6 billion to buy migraine pill maker Biohaven Pharmaceutical. It is the biggest deal the drugmaker has made since 2016 in order to beef up its portfolio ahead …

Jan 5, 2022 · In connection with the closing of the equity purchase and effectiveness of the strategic transaction, Pfizer made an upfront payment to Biohaven of $500 million, consisting …

Oct 4, 2022 · Pfizer announced on Oct. 3, 2022 that it has completed its acquisition of Biohaven Pharmaceuticals, the maker of NURTEC ODT (rimegepant), a migraine therapy approved for …

Oct 3, 2022 · We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking …

Biohaven Pharmaceutical Holding Company, a small innovator with a revolutionary treatment to both treat and prevent migraines called NURTEC ® ODT, successfully commercialized its …

May 10, 2022 · Pfizer has agreed to acquire Biohaven Pharmaceuticals for $11.6 billion in a deal that turns an existing alliance on a fast-selling migraine drug into a big bet on its future growth.